Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) Revenue (2018 - 2025)

Dna X filings provide 8 years of Revenue readings, the most recent being $16.2 million for Q3 2025.

  • On a quarterly basis, Revenue rose 7.94% to $16.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $51.7 million, a 5.39% increase, with the full-year FY2024 number at $50.9 million, down 45.62% from a year prior.
  • Revenue hit $16.2 million in Q3 2025 for Dna X, up from $11.2 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $27.6 million in Q3 2023 to a low of $7.6 million in Q4 2024.
  • Median Revenue over the past 5 years was $14.4 million (2021), compared with a mean of $16.1 million.
  • Biggest five-year swings in Revenue: soared 124.47% in 2023 and later tumbled 64.66% in 2024.
  • Dna X's Revenue stood at $15.9 million in 2021, then skyrocketed by 51.39% to $24.1 million in 2022, then tumbled by 44.32% to $13.4 million in 2023, then plummeted by 43.37% to $7.6 million in 2024, then soared by 113.2% to $16.2 million in 2025.
  • The last three reported values for Revenue were $16.2 million (Q3 2025), $11.2 million (Q2 2025), and $16.7 million (Q1 2025) per Business Quant data.